Back to top
more

uniQure (QURE)

(Delayed Data from NSDQ)

$4.75 USD

4.75
461,597

+0.03 (0.64%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $4.76 +0.01 (0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 0.65% and 109.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Pfizer's (PFE) Hemophilia Candidate BLA Gets FDA Acceptance

by Zacks Equity Research

The FDA decision on Pfizer's (PFE) BLA for marstacimab for hemophilia A and B is expected in the fourth quarter of 2024, while the European Commission's decision is expected in 2025.

Wall Street Analysts Believe uniQure (QURE) Could Rally 405.37%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for uniQure (QURE) points to a 405.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of -26.17% and 57.68%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses.

Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UniQure (QURE) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekta Bagri headshot

Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback

by Ekta Bagri

Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.

uniQure (QURE) Up on Restructuring Plans, Workforce Reduction

by Zacks Equity Research

uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.

UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of -148.48% and 98.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing

by Zacks Equity Research

A final decision on Pfizer's (PFE) BLA filing, seeking approval for hemophilia B gene therapy, treatment is expected by second-quarter 2024.

uniQure (QURE) Falls on Mixed Huntington's Disease Study Results

by Zacks Equity Research

uniQure (QURE) stock declines after the company announces mixed results from its biomarkers analysis in the early-to-mid-stage study of AMT-130 in Huntington's disease.

Pfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study

by Zacks Equity Research

Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.

UniQure (QURE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of -59.80% and 79.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in UniQure (QURE) Stock?

by Zacks Equity Research

Investors need to pay close attention to UniQure (QURE) stock based on the movements in the options market lately.

UniQure (QURE) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 128.85% and 85.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Pfizer's (PFE) Hemophilia B Gene Therapy Meets Study Goal

by Zacks Equity Research

Data from a late-stage study shows that treatment with Pfizer's (PFE) hemophilia B gene therapy resulted in a 71% reduction in annualized bleed rate (ABR) compared to standard-of-care treatment.

uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy

by Zacks Equity Research

uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.

UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 8.11% and 86.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate uniQure (QURE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urogen Pharma (URGN) Moves 10.3% Higher: Will This Strength Last?

by Zacks Equity Research

Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 12.50% and 97.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

uniQure (QURE) Up on Safety Data From Huntington's Disease Study

by Zacks Equity Research

uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.